The Singing Shop chairman Tunku Arishah Tunku Maamor (second from right), her husband AmBank Group chairman Tan Sri Azman Hashim (second from right), Shalina Azman (left), The Singing Shop former director Datuk Esther Tan Choon Hwa (right) and its first vocal instructor Tony Carpio (back row, second from right) at the official opening of Tunku Arishah’s Gallery (T.A’s Gallery) at The AmpWalk Mall in Kuala Lumpur recently. T.A’s Gallery is new home for The Singing Shop in Kuala Lumpur. Source : The Star
0 Comments
KUALA LUMPUR, Dec 22 (Bernama) – Malaysian Genomics Resource Centre Berhad (Malaysian Genomics) and its subsidiary, Clinipath Malaysia Sdn Bhd, observed an increased genetic risks for adverse drug reactions (ADR) to cardiovascular drugs among Malaysian patients.
The company conducted pharmacogenetic screening using Malaysian Genomics’ Dtect® PGx genetic screening test on DNA samples from more than 50 Malaysian individuals of different ethnicities, genders and ages. "ADRs for 27 cardiovascular medications were tested. "Results from the Malaysian samples indicate an increased risk for ADRs for 103 out of 198 commonly prescribed drugs included in the test," it said in a statement today. It said, notably, 42 percent of individuals tested had genetic mutations associated with reduced response to Clopidogrel, an antiplatelet drug commonly prescribed to reduce the risk of heart disease and stroke. In addition, 13 percent of individuals had genetic mutations associated with high risk of ADRs to Simvastatin, a drug commonly prescribed to lower cholesterol and triglyceride levels in the blood. Meanwhile, based on the published literature, the rates of ADR for Caucasians are typically 20 percent and two percent respectively. The statement added that the difference in genetic make-up between Malaysian and Caucasian or other populations could explain the higher prevalence of some of the genetic mutations associated with increased ADRs. -- BERNAMA LES ULIS, France, Dec 22 (Bernama-BUSINESS WIRE) -- On December 20th, a decree from the President of France was published in Le Journal Officiel* appointing Denis DELVAL CEO of LFB S.A. This decree follows the General Meeting of LFB SA and the meeting of its Board of Directors, which both took place on December 4th, 2017.
Denis DELVAL is also appointed, CEO of LFB BIOMEDICAMENTS and President of LFB BIOTECHNOLOGIES as of December 4th, following Christian BÉCHON and Denis SOUBEYRAN’s departures. A graduate of ESSEC and INSEAD business schools with a PhD in Pharmacy, Denis DELVAL has a deep understanding of the pharmaceutical industry. He has held important marketing, sales and strategic positions in France, Europe and worldwide and has managed international partnerships within various pharmaceutical groups (Bayer, Fournier Pharma, ALK). In 2006, he was appointed General Manager of ALK France. In 2012, he also became Senior Vice President of the Danish pharmaceutical company specialized in allergy immunotherapy treatments. Denis DELVAL lectures at ESSEC business school and has also been Chairman of Lecrip.org, a healthcare think tank. “I am proud to be appointed as CEO of LFB Group and to work for this company operating in a strategic sector. LFB produces therapeutics that are essential for the lives of thousands of patients, particularly in the rare disease field. I am fully aware of the challenges ahead and look forward to unleashing energies to make this pharmaceutical company successful in France and internationally.” * The Official Journal of the French Republic. About LFB Group LFB is a biopharmaceutical group that develops, manufactures, and markets medicinal products derived from living matter for the treatment of serious and often rare diseases in several major therapeutic fields, including Hemostasis, Immunology and Intensive Care. LFB is the leading manufacturer of plasma-derived medicinal products in France and 7th worldwide, and is also among the leading European companies for the development of new-generation medicinal products or treatments based on biotechnologies. Through its constant research efforts, the LFB group implements a growth strategy to expand its activities on international markets. Today, LFB currently markets its products in almost 60 countries around the world with a global turnover of €518.9 million in 2016. LFB group employs more than 2300 people worldwide. www.groupe-lfb.com Contacts LFB SA Sandrine Charrières, Tel : +33-(0)1-6982-7280 Executive VP Corporate Communications [email protected] Source: LFB S.A. NEW YORK, Dec 21 (Bernama-BUSINESS WIRE) -- Starr Companies today announced the appointment of Steve Blakey as president and chief executive officer of Starr Insurance Holdings.
“We are pleased to introduce Steve as our new Company President. With over 35 years of experience, including establishing Starr’s presence in the United Kingdom and throughout Europe as well as making Starr one of the leading providers of aviation and aerospace insurance in the world, Steve is uniquely qualified to lead the company going forward,” stated Maurice R. Greenberg, chairman, Starr Companies. Steve Blakey replaces Chuck Dangelo, who has announced his retirement. “After 46 years in the insurance industry, we would like to thank Chuck for his contributions to our company and industry. He has been instrumental in leading Starr’s growth and we wish him well in his retirement.” About Starr Companies Starr Companies (Starr) is the worldwide marketing name for the operating insurance and travel assistance companies and subsidiaries of Starr International Company, Inc. and for the investment business of C.V. Starr & Co., Inc. and its subsidiaries. Starr is a leading insurance and investment organization with a presence on five continents; through its operating insurance companies, Starr provides property, casualty, and accident & health insurance products as well as a range of specialty coverages including aviation, marine, energy and excess casualty insurance. The following insurance company subsidiaries each have an A.M. Best rating of “A” (Excellent): Starr Indemnity & Liability Company, Starr Surplus Lines Insurance Company, Starr Syndicate Limited at Lloyd's of London, Starr International Insurance (Asia) Ltd., and Starr Insurance & Reinsurance Limited. For more information visit us at www.starrcompanies.com Contacts Starr Companies Paula Negro, 212-884-0561 Director of Content, Communications and Media Relations [email protected] Source: Starr Companies View this news release online at: http://www.businesswire.com/news/home/20171219006237/en --BERNAMA KUALA LUMPUR, Dec 22 (Bernama) -- We refer to the announcement dated 11 December 2017 made by OldTown on the Pre-Conditional Voluntary Offer.
Pursuant to Paragraph 19.04(1) of the Rules, we wish to inform that CIMB Investment Bank Berhad, who has been appointed as an adviser to the Offeror in connection with the Pre-Conditional Voluntary Offer has dealt in the securities of OldTown on 21 December 2017 for its discretionary client, details of which are as follows : http://mrem.bernama.com/viewsm.php?idm=30843 |
Archives
April 2023
|